New Delhi, May 13 -- Cipla is building a biosimilars pipeline, and aims to steadily add products over the next five years, its top executive said, as the company bets on the fast-growing market for cheaper versions of complex biologic drugs.

"We are advancing our opportunities in biosimilars and other complex modalities, where we see a significant long-term opportunity," managing director and global chief executive officer (CEO) Achin Gupta told reporters in Mumbai on Wednesday.

In March, the Mumbai-headquartered pharma giant announced a joint venture with biologics contract drug manufacturer Kemwell Biopharma, where they are building "a focused pipeline aligned to our core strengths and continuing to maintain a disciplined market-led a...